This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Select Medical (SEM) Up 18% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners
by Zacks Equity Research
Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.
3 Medical Services Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.
Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround
by Zacks Equity Research
Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
New Strong Buy Stocks for August 15th
by Zacks Equity Research
SGRY, DFH, CDRE, DHI and KB have been added to the Zacks Rank #1 (Strong Buy) List on August 15, 2023.
Compared to Estimates, Surgery Partners (SGRY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Surgery Partners (SGRY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Surgery Partners (SGRY): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 900% and 3.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 28.57% and 2.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of -77.78% and 11.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Surgery Partners (SGRY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -150% and 0.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Surgery Partners (SGRY) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Surgery Partners (SGRY) stock based on the movements in the options market lately.
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -80% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -11.54% and 2.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 35% Upside in Surgery Partners (SGRY): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 34.6% upside potential for Surgery Partners (SGRY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Surgery Partners (SGRY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ortho Clinical Diagnostics (OCDX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ortho Clinical (OCDX) delivered earnings and revenue surprises of 20% and 0.39%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?